BioXcel stock: buy or sell?
February 21st, 2020
Should I buy BioXcel stock?Even if you are a experienced or a novel trader, best trading results come from using an investing strategy that never leaves to random or subjective opinions when is the best moment to buy or sell stocks. That's why is so important to define your own trading plan that fits your character as inversor. At Stocks2.com, we use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.
Just 1 of our buy setups matches with BioXcel stock now:
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||Yes|
Is BioXcel stock a buy?
Everyday, hundreds of stock ratings are posted by financial analysts to indicate a particular stock's attractiveness.Unfortunately, we couldn't find any rating for BTAI stock for the last month.
BioXcel stock analysis
BioXcel Therapeutics soared 2.02% today to $34.89 after reaching all time highs on Tuesday.
After topping to all time highs on Tuesday, BioXcel soared 2.02% today to $34.89. Since SMA100d and SMA200d crossed up on February 19th, BTAI price slid a -11.87%. Since December when BTAI stock price broke up the SMA200d line, it gained $26.58 (319.86%). BTAI is retaking the upward trend marking a new rising bottom heading to break out over $43.63. On Tuesday, BTAI hit new all time highs, pushing higher previous ATH of $41.59 recorded on February/14. New ATHs are usual entry points for many trading setups as there aren't higher resistences.
BioXcel set new all time highs again this week, marking to $43.63. Shares ended at $34.89 and plummed -5.63% during the week. Last week BTAI boosted a super good 45.90% in just one week.
In a weekly time frame, BioXcel Therapeutics stock is drawing an uptrend with rising tops and bottoms. Now trading in between its last bottom and last top, BTAI might consolidate in a flat-base, waiting to break out over or down under . Last week, SMA20w and SMA40w crossed up triggering a rise of 74.45%. Since late December 2019 when BTAI stock price broke up the SMA40w line, it gained $26.58 (319.86%).
BioXcel stock price history
BioXcel IPO was on March 8th, 2018 at $11.02 per share1. Since then, BTAI stock grew a 216.60%, with a yearly average of 216.60%. If you had invested right after BTAI's IPO a $1,000 in BioXcel stock in 2018, it would worth $2,166.00 today.
1: Adjusted price after possible price splits or reverse-splits.
BioXcel stock historical price chart
BTAI stock reached all-time highs on Tuesday with a price of $43.63.
BioXcel stock price targetHow much a stock will be priced tomorrow or next week is quite unpredictable However, banks and other financial institutions analysts, with the help of lots of data and algorithms do their best to predict the stock prices movement. The accuracy of these stock price predictions is not very high, and you should not blindly believe and make decisions only based on what this ratings or price target predictions say. For the last month we have not detected any price prediction for BioXcel Therapeutics stock by any trusted analyst.
Financials and fundamental analysis
Earnings date and Earnings per ShareBioXcel Therapeutics presented super good results for 2018-Q4 on March. BioXcel rocketed Earnings per Share (EPS) by 38.20%, beating analysts of $-0.34. BioXcel posted $-0.47.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn , BioXcel Therapeutics annual sales to M dollars from marked in . When comparing vs , , profit margin (that is, the net income divided by revenues) a to .
Quarterly financial resultsReported quarter earnings marked $-7.08 M with a profit margin of . Profit margin stayed steady a 0.00% compared to previous quarter when profit margin was inf%. When comparing revenues to same quarter last year, BioXcel Therapeutics sales marked a tight move and stayed stable a nan%. Looking back to recent quarterly results, BioXcel Therapeutics posted 7 negative quarters in a row.
BioXcel ownershipWhen you are planning to invest in a company, it's always worth to check its ownership structure.
Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For BioXcel, 53.84% of all outstanding shares are owned by its staff.
In case of BioXcel Therapeutics stock, 28.08% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for BTAI stock account 0.00%, no big difference from last month.
The following table compares ownership indicators for other stocks related to BioXcel:
|Market cap||$629.4 M|
|Total shares||18.0 M|
|Float shares||8.3 M|
|- Institutional holdings (%)||28.1%|
|- Insider holdings (%)||53.8%|
|Shares in short selling||0.0%|
|Friday, February 21st, 2020|
|Day range||$34.06 - $37.50|
|Average true range||$4.76|
|50d mov avg||$16.74|
|100d mov avg||$11.14|
|200d mov avg||$10.69|
BioXcel performanceStocks performance is always measured in comparision to the market or competitors and related stocks in the same industry. In the following table, we compare BioXcel Therapeutics performance to :